Is There a Dimmer Outlook Ahead for Adverum Biotechnologies Inc. (ADVM)? – News Heater

Is There a Dimmer Outlook Ahead for Adverum Biotechnologies Inc. (ADVM)?

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Adverum Biotechnologies Inc. (NASDAQ:ADVM) went up by 1.83% from its latest closing price compared to the recent 1-year high of $26.98. The company’s stock price has collected -58.95% of loss in the last five trading sessions. Press Release reported on 05/01/21 that Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Is It Worth Investing in Adverum Biotechnologies Inc. (NASDAQ :ADVM) Right Now?

Plus, the 36-month beta value for ADVM is at 1.15. Opinions of the stock are interesting as 4 analysts out of 10 who provided ratings for Adverum Biotechnologies Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 6 rated it as “hold,” and 0 as “sell.”


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



The average price from analysts is $9.13. ADVM currently public float of 96.74M and currently shorts hold a 12.07% ratio of that float. Today, the average trading volume of ADVM was 1.70M shares.

ADVM’s Market Performance

ADVM stocks went down by -58.95% for the week, with a monthly drop of -60.45% and a quarterly performance of -68.37%, while its annual performance rate touched -67.09%. The volatility ratio for the week stands at 9.30% while the volatility levels for the past 30 days are set at 6.56% for Adverum Biotechnologies Inc.. The simple moving average for the period of the last 20 days is -57.71% for ADVM stocks with a simple moving average of -68.61% for the last 200 days.

Analysts’ Opinion of ADVM

Many brokerage firms have already submitted their reports for ADVM stocks, with Truist repeating the rating for ADVM by listing it as a “Hold.” The predicted price for ADVM in the upcoming period, according to Truist is $9 based on the research report published on April 29th of the current year 2021.

RBC Capital Mkts, on the other hand, stated in their research note that they expect to see ADVM reach a price target of $6. The rating they have provided for ADVM stocks is “Sector Perform” according to the report published on April 29th, 2021.

Chardan Capital Markets gave a rating of “Neutral” to ADVM, setting the target price at $5 in the report published on April 29th of the current year.

ADVM Trading at -62.51% from the 50-Day Moving Average

After a stumble in the market that brought ADVM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.54% of loss for the given period.

Volatility was left at 6.56%, however, over the last 30 days, the volatility rate increased by 9.30%, as shares sank -61.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -69.63% lower at present.

During the last 5 trading sessions, ADVM fell by -58.95%, which changed the moving average for the period of 200-days by -78.43% in comparison to the 20-day moving average, which settled at $8.91. In addition, Adverum Biotechnologies Inc. saw -64.02% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ADVM starting from Fischer Laurent, who purchase 10,000 shares at the price of $9.88 back on Mar 24. After this action, Fischer Laurent now owns 26,292 shares of Adverum Biotechnologies Inc., valued at $98,780 using the latest closing price.

Machado Patrick, the Director of Adverum Biotechnologies Inc., purchase 10,000 shares at $9.92 during a trade that took place back on Mar 24, which means that Machado Patrick is holding 88,182 shares at $99,196 based on the most recent closing price.

Stock Fundamentals for ADVM

The total capital return value is set at -35.08, while invested capital returns managed to touch -35.40. Equity return is now at value -31.60, with -28.10 for asset returns.

Based on Adverum Biotechnologies Inc. (ADVM), the company’s capital structure generated 7.08 points at debt to equity in total, while total debt to capital is 6.61. Total debt to assets is 6.37, with long-term debt to equity ratio resting at 6.05. Finally, the long-term debt to capital ratio is 5.65.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

The liquidity ratio also appears to be rather interesting for investors as it stands at 20.82.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.